Bromocriptine Quick-Release as Adjunct Therapy in Youth and
Forty adolescents and adults with type 1 diabetes ages 12-60 years were enrolled in a double-blind, placebo-controlled, random order crossover study of 4 weeks of treatment in the morning with BCQR (titrated weekly from 0.8 mg to 1.6 mg to 3.2 mg, minimum dose 1.6 mg). Adolescents displayed baseline hyperglycemia, insulin resistance, metabolic dysfunction, and increased renal filtration compared to adults. In both age groups, CGM measures, eIS and insulin dose did not differ with BCQR treatment. In adolescents, BCQR decreased systolic BP, diastolic BP and triangular index and increased serum creatinine. In adults, systolic BP, mean arterial pressure (MAP), systemic vascular resistance, and MMTT glucose and glucagon-like peptide 1 AUC's were lower, and orthostatic drop in systolic BP was greater with BCQR.